(TBPH) Theravance Biopharma - Ratings and Ratios
COPD, Nebulizer, Ampreloxetine, TRELEGY, Revefenacin
TBPH EPS (Earnings per Share)
TBPH Revenue
Description: TBPH Theravance Biopharma October 23, 2025
Theravance Biopharma Inc. (NASDAQ: TBPH) is a U.S.-based biopharmaceutical firm that focuses on developing and commercializing specialty medicines, primarily for respiratory and neurological disorders. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Its commercial portfolio includes YUPELRI™ (revefenacin), a once-daily nebulized long-acting muscarinic antagonist approved for chronic obstructive pulmonary disease (COPD). In Q2 2024, YUPELRI generated approximately $45 million in net sales-a figure that reflects a ~ 12% year-over-year growth rate, assuming the company’s latest earnings release (subject to revision). The pipeline features Ampreloxetine, a Phase III-completed norepinephrine reuptake inhibitor for neurogenic orthostatic hypotension, and TRELEGY®, a triple-therapy inhaler for COPD and asthma. Theravance’s strategic collaboration with Viatris Inc. provides co-development and co-commercialization rights for revefenacin, sharing both development costs and market risk.
Key sector drivers include an aging U.S. population (people ≥ 65 years now represent ≈ 16% of the population, projected to rise to 22% by 2035) and the growing prevalence of COPD, which the Global Initiative for Chronic Obstructive Lung Disease (GOLD) estimates will affect ≈ 16 million Americans, supporting a market size of roughly $13 billion in 2025. Theravance’s R&D spend of about $150 million in FY 2024 (≈ 15% of revenue) underscores its commitment to pipeline expansion, but the company remains exposed to regulatory timelines and reimbursement pressures. For a deeper, data-driven valuation analysis, consider exploring ValueRay’s detailed financial models and scenario testing tools.
TBPH Stock Overview
| Market Cap in USD | 714m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2014-05-16 |
TBPH Stock Ratings
| Growth Rating | 45.8% |
| Fundamental | 82.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 52.0% |
| Analyst Rating | 3.75 of 5 |
TBPH Dividends
Currently no dividends paidTBPH Growth Ratios
| Growth Correlation 3m | 77% |
| Growth Correlation 12m | 78.1% |
| Growth Correlation 5y | -26.9% |
| CAGR 5y | 11.22% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.31 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.70 |
| Sharpe Ratio 12m | 0.11 |
| Alpha | 76.77 |
| Beta | -0.026 |
| Volatility | 40.22% |
| Current Volume | 488.8k |
| Average Volume 20d | 263.4k |
| Stop Loss | 14.4 (-3.7%) |
| Signal | -0.23 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (13.0m TTM) > 0 and > 6% of Revenue (6% = 4.63m TTM) |
| FCFTA 0.57 (>2.0%) and ΔFCFTA 60.11pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 403.7% (prev 155.4%; Δ 248.3pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.58 (>3.0%) and CFO 245.0m > Net Income 13.0m (YES >=105%, WARN >=100%) |
| Net Debt (-235.5m) to EBITDA (46.1m) ratio: -5.11 <= 3.0 (WARN <= 3.5) |
| Current Ratio 6.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (50.7m) change vs 12m ago 4.06% (target <= -2.0% for YES) |
| Gross Margin 98.23% (prev 72.33%; Δ 25.90pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 19.59% (prev 17.13%; Δ 2.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 16.54 (EBITDA TTM 46.1m / Interest Expense TTM 2.58m) >= 6 (WARN >= 3) |
Altman Z'' -6.37
| (A) 0.73 = (Total Current Assets 366.3m - Total Current Liabilities 54.6m) / Total Assets 426.0m |
| (B) -2.17 = Retained Earnings (Balance) -924.3m / Total Assets 426.0m |
| warn (B) unusual magnitude: -2.17 — check mapping/units |
| (C) 0.11 = EBIT TTM 42.7m / Avg Total Assets 394.0m |
| (D) -4.59 = Book Value of Equity -924.3m / Total Liabilities 201.2m |
| Total Rating: -6.37 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 82.94
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 58.10% = 5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.21 = 2.48 |
| 5. Debt/Ebitda -5.11 = 2.50 |
| 6. ROIC - WACC (= 11.37)% = 12.50 |
| 7. RoE 6.93% = 0.58 |
| 8. Rev. Trend 73.59% = 5.52 |
| 9. EPS Trend 67.36% = 3.37 |
What is the price of TBPH shares?
Over the past week, the price has changed by +5.50%, over one month by +2.54%, over three months by +34.81% and over the past year by +80.77%.
Is Theravance Biopharma a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TBPH is around 16.58 USD . This means that TBPH is currently undervalued and has a potential upside of +10.9% (Margin of Safety).
Is TBPH a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TBPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20 | 33.8% |
| Analysts Target Price | 20 | 33.8% |
| ValueRay Target Price | 18 | 20.5% |
TBPH Fundamental Data Overview October 31, 2025
P/E Trailing = 59.0417
P/E Forward = 9.434
P/S = 9.2432
P/B = 3.1514
P/EG = -0.05
Beta = -0.026
Revenue TTM = 77.2m USD
EBIT TTM = 42.7m USD
EBITDA TTM = 46.1m USD
Long Term Debt = 46.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.9m USD (from shortTermDebt, last quarter)
Debt = 46.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -235.5m USD (from netDebt column, last quarter)
Enterprise Value = 421.3m USD (713.6m + Debt 46.5m - CCE 338.8m)
Interest Coverage Ratio = 16.54 (Ebit TTM 42.7m / Interest Expense TTM 2.58m)
FCF Yield = 58.10% (FCF TTM 244.8m / Enterprise Value 421.3m)
FCF Margin = 317.0% (FCF TTM 244.8m / Revenue TTM 77.2m)
Net Margin = 16.88% (Net Income TTM 13.0m / Revenue TTM 77.2m)
Gross Margin = 98.23% ((Revenue TTM 77.2m - Cost of Revenue TTM 1.36m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 100.0%)
Tobins Q-Ratio = 0.99 (Enterprise Value 421.3m / Total Assets 426.0m)
Interest Expense / Debt = 1.43% (Interest Expense 663.0k / Debt 46.5m)
Taxrate = 25.09% (18.4m / 73.2m)
NOPAT = 32.0m (EBIT 42.7m * (1 - 25.09%))
Current Ratio = 6.70 (Total Current Assets 366.3m / Total Current Liabilities 54.6m)
Debt / Equity = 0.21 (Debt 46.5m / totalStockholderEquity, last quarter 224.8m)
Debt / EBITDA = -5.11 (Net Debt -235.5m / EBITDA 46.1m)
Debt / FCF = -0.96 (Net Debt -235.5m / FCF TTM 244.8m)
Total Stockholder Equity = 188.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.06% (Net Income 13.0m / Total Assets 426.0m)
RoE = 6.93% (Net Income TTM 13.0m / Total Stockholder Equity 188.0m)
RoCE = 18.19% (EBIT 42.7m / Capital Employed (Equity 188.0m + L.T.Debt 46.5m))
RoIC = 16.99% (NOPAT 32.0m / Invested Capital 188.0m)
WACC = 5.62% (E(713.6m)/V(760.1m) * Re(5.92%) + D(46.5m)/V(760.1m) * Rd(1.43%) * (1-Tc(0.25)))
Discount Rate = 5.92% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 1.32%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈244.8m ; Y1≈160.7m ; Y5≈73.5m
Fair Price DCF = 28.68 (DCF Value 1.44b / Shares Outstanding 50.4m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 67.36 | EPS CAGR: 21.06% | SUE: 0.47 | # QB: 0
Revenue Correlation: 73.59 | Revenue CAGR: 31.06% | SUE: 0.04 | # QB: 0
Additional Sources for TBPH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle